Migraine Headaches: The Immunologist's View by Theoharides, Theoharis C.
IMMUNOLOGY OF MIGRAINE
79
Migraine Headaches: 
The Immunologist’s View
Theoharis C. Theoharides, Ph.D, M.D.
A B S T R A C T
OBJECTIVE: Review evidence supporting the role of mast cells in migraine patho-
physiology. BACKGROUND: Mast cells are known for their role in allergic reactions, 
but they are also important in immunity and inflammatory diseases, especially 
those precipitated or worsened by stress. Such are migraine headaches that are 
associated with spreading neuronal depression and neurogenic inflammation intra-
cranially. Migraines are also comorbid with allergies and could precipitate acute 
coronary syndromes (ACS). Mast cells are located perivascularly, in close association 
with neurons, especially in the meninges. Mast cells can be activated by trigeminal 
nerve stimulation and by acute stress, leading to increased vascular permeability 
and neurogenic inflammation dependent on NK-1 receptors, but not necessarily on 
substance P (SP). METHODS: We reviewed relevant literature and summarized our 
own findings. RESULTS: Corticotropin-releasing hormone (CRH), a mediator of the 
stress response released from the hypothalamus, can activate CRH receptors either 
on the sensory nuclei of the trigeminal nerve or directly on the mast cells. They, then 
release proinflammatory, nociceptive and vasoactive mediators including histamine, 
tryptase and vascular endothelial growth factor (VEGF), thereby triggering migraine 
headaches. CONCLUSIONS: These results indicate that there are several novel points 
of intervention for the development of therapeutic agents to help alleviate migraines. 
Preliminary clinical studies with brain mast cell blockers and CRH receptor antago-
nists suggest that they could be useful prophylactically.
1 .  S E L E C T I V E  R E L E A S E  O F  M A S T  C E L L  M E D I A T O R S
Mast cells derive from a distinct precursor in the bone marrow [1] and mature 
under local tissue microenvironmental factors [2]. Mast cells are necessary for the 
development of allergic reactions, through crosslinking of their surface receptors 
for IgE (FcåRI), leading to degranulation and the release of vasoactive, pro-inflam-
matory and nociceptive mediators that include histamine, cytokines and proteolytic 
enzymes [3,4] (Table 1). The multitude of mediators that could be secreted, especially 
in response to many non-immunologic triggers (Table 2) has given rise to new specula-
tions about the possible role of mast cells in immune responses, especially acquired 
immunity5 and inflammation [6].
Unlike allergic reactions, mast cells are rarely seen to degranulate during autoim-
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mune [7] or inflammatory processes [8]. Instead, mast cells 
can secrete mediators without overt degranulation [9], through 
differential or selective release [10], probably regulated by the 
action of distinct protein kinases on a unique phosphoprotein 
[11,12]. In such cases, mast cells undergo ultrastructural al-
terations of their electron dense granular core indicative of 
secretion, but without overt degranulation, a process that has 
been termed “activation” [13-15] “intragranular activation” 
[16] or “piecemeal” degranulation [17]. Selective release has 
been reported for a number of mediators [18-20], especially 
serotonin [10], eicosanoids [21-23] or IL-6 [24-27]. In fact, 
we showed that interleukin-1 (IL-1) can stimulate human 
mast cells to release IL-6 selectively without degranulation, 
through a unique process utilizing 40-80 nm vesicles unrelated 
to the secretory granules (800-1000 nm) [28]. We also recently 
showed that corticotropin releasing hormone (CRH) secreted 
under stress can stimulate human mast cells through specific 
CRH receptors to release vascular endothelial growth factor 
(VEGF) selectively [29].
These findings suggest that mast cells may also be involved 
in inflammatory diseases [6,30] that include migraines [31] 
and cardiovascular disease [32].
2 .  M E N I N G E A L  I N F L A M M A T I O N  A N D  
M I G R A I N E S
Migraine headache is still a descriptive term that has been 
used primarily to refer to the brain and is usually associated 
with meningeal and cerebral vasodilation, as well as “spread-
ing” neuronal depression [33]. It was hypothesized that mast 
cells may be ber involved in the pathophysiology of migraines 
[31]. Mast cells are located in close apposition to neurons in 
the meninges [34,35] and can be activated by neuropeptides 
[36], by antidromic nerve stimulation [14], as well as by acute 
immobilization stress [15]. Brain mast cells were also activated 
by acute stress leading to increased vascular permeability [37], 
effects dependent on mast cells and CRH [38].
Stress is known to precipitate or exacerbate migraines, 
raising the possibility of some underlying pathologic mecha-
nism. One such possibility comes from one study of children 
migraineurs, in whom the frequency and severity of migraines 
was reduced, along with the unique mast cell biochemical 
marker tryptase, when they were taught relaxation techniques 
[39]. Recent studies have shown that stress-induced neuro-
genic inflammation depends on NK-1 receptors, but does not 
require SP [40], while it may involve a direct action of CRH 
on brain microvessels [41]. Yet, delayed responses may also 
involve IL-6 and nitric oxide elevations in dura macrophages 
[42]. These findings have led to a new model for the patho-
genesis of intracranial neurogenic inflammation (Fig. 1) that 
calls for hypothalamic CRH acting on the sensory nucleus of 
the trigeminal nerve, which has been reported to express CRH 
receptors [43]; CRH could then secrete mast cell stimulating 
peptides and/or have a direct action on mast cells and/or on the 
vasculature [6]. These processes have recently been reviewed 
[44], as has been the important role of mast cells in migraine 
pathophysiology [45].
C O N C L U S I O N
In summary, the mast cell has emerged as a unique im-
mune cell that could be activated by many non-immune pro-
TABLE 1. Mast cell Triggers
Antigen + IgE
Anaphylatoxins
CRH
IL-1
Immunoglobulin – free light chains
LPS
NGF
NT
SCF
SP
Superantigens
Ucn
VIP
Viral DNA sequences
FIGURE 1. Schematic representation of the sequence of events 
that may induce brain mast cell activation and neurogenic in-
flammation, leading to migraines.
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TABLE 2. Mast Cell Mediators
Mediators                                                                        Main Pathophysiologic Effects
Prestored
 Biogenic Amines
  Histamine                                                                  Vasodilation, angiogenesis, mitogenesis, pain
  5-Hydroxytryptamine (5-HT, serotonin)                Vasoconstriction, pain
 Chemokines
  IL-8, MCP-1, MCP-3, MCP-4, RANTES               Chemoattraction and tissue infiltration of leukocytes
 Enzymes
  Arylsulfatases                                                            Lipid/proteoglycan hydrolysis
  Carboxypeptidase A                                                 Peptide processing
  Chymase                                                                    Tissue damage, angiotensin II synthesis, cholesterol liberation
  Kinogenases                                                              Synthesis of vasodilatory kinins, pain
  Phospholipases                                                          Arachidonic acid generation
  Tryptase                                                                     Tissue damage, activation of PAR, inflammation, pain
 Peptides
  Corticotropin-releasing hormone (CRH)              Inflammation, vasodilation
  Endorphins                                                                Analgesia
  Endothelin                                                                 Sepsis
  Kinins (bradykinin)                                                  Inflammation, pain, vasodilation
  Somatostatin (SRIF)                                                Anti-inflammatory (?)
  Substance P (SP)                                                      Inflammation, pain
  Vasoactive intestinal peptide (VIP)                       Vasodilation
  Urocortin                                                                   Inflammation, vasodilation
  Vascular endothelial growth factor (VGEF)         Neovascularization, vasodilation
 Proteoglycans
  Chondroitin sulfate                                                  Cartilage synthesis, anti-inflammatory
  Heparin                                                                     Angiogenesis, nerve growth factor stabilization
  Hyaluronic acid                                                         Connective tissue, nerve growth factor stabilization
De novo synthesized
 Cytokines
  Interleukins (IL)-1,2,3,4,5,6,9,10,13,16                   Inflammation, leukocyte migration, pain
  INF-ã; MIF; TNF-á                                                 Inflammation, leukocyte proliferation/activation
 Growth Factors
  SCF, GM-CSF, b-FGF, NGF, VEGF                    Growth of a variety of cells
 Phospholipid metabolites
  Leukotriene B4 LTB4                                             Leukocyte chemotaxis
  Leukotriene C4 (LTC4)                                           Vasoconstriction, pain
  Platelet activating factor (PAF)                              Platelet activation, vasodilation
  Prostaglandin D2 (PGD2)                                       Bronchonstriction, pain
 Nitric oxide (NO)                                                                Vasodilation
b-FGF= fibroblast growth factor, CRH= corticotropin-releasing hormone, CSF= colony stimulating factor, GM-CSF= granulocyte monocyte-
colony stimulating factor, INFã= Interferon-ã, MIF= macrophage inflammatory factor, NGF= nerve growth factor, SCF= Stem cell factor, 
SRIF= somatomedin release inhibitory factor, somatostatin, TGF-â= transforming growth factor-â, TNF-á= tumor necrosis factor-á, VEGF= 
vascular endothelial growth factor
cesses, including acute stress, 46 and could participate in a 
variety of inflammatory diseases including the brain [30].
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